Form 13G TENAX THERAPEUTICS For: 8 April

Investment management firm TENAX THERAPEUTICS filed a Form 13G with the U.S. Securities and Exchange Commission (SEC) on 8 April, disclosing its significant ownership stake in a publicly traded company. The filing, a mandatory regulatory disclosure for major shareholders, was submitted to the SEC's headquarters in Washington, D.C., as required by securities law when an entity's holdings exceed 5% of a company's outstanding shares. This action provides transparency to the market and other investors regarding substantial ownership positions. Form 13G is a shortened version of the more detailed Form 13D, typically used by passive investors who are not seeking to influence or control the management of the company. The filing by TENAX THERAPEUTICS indicates it has crossed the 5% ownership threshold, but its investment is likely intended as a long-term holding rather than an activist stake. Such disclosures are closely monitored by market analysts and institutional investors as signals of confidence or strategic interest in a particular firm. The filing contributes to the public record of ownership for the company in which TENAX THERAPEUTICS has invested, although the specific target company was not named in the provided information. In the broader economic context, these routine regulatory filings are essential for maintaining fair and orderly capital markets, ensuring all participants have access to material information about significant shareholdings that could impact a stock's liquidity and governance.